Myriad Genetics (MYGN)
(Delayed Data from NSDQ)
$26.47 USD
+0.04 (0.15%)
Updated Oct 4, 2024 03:59 PM ET
After-Market: $26.48 +0.01 (0.04%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$26.47 USD
+0.04 (0.15%)
Updated Oct 4, 2024 03:59 PM ET
After-Market: $26.48 +0.01 (0.04%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Zacks News
Coherus BioSciences (CHRS) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 1.64% and 11.94%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Myriad Genetics (MYGN) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Hold on to Myriad Genetics (MYGN) for Now
by Zacks Equity Research
Investors are optimistic about Myriad Genetics (MYGN), given robust volume growth for GeneSight and prenatal testing.
Myriad Genetics (MYGN) Q3 Loss Wider Than Expected, Revenues Top
by Zacks Equity Research
Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment drove Q3 sales despite a challenging business environment.
Myriad Genetics (MYGN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Myriad (MYGN) delivered earnings and revenue surprises of -300.00% and 1.80%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain LabCorp (LH) Stock For Now
by Zacks Equity Research
Strength in Drug Development business and new strategies to expand into high-growth markets raise optimism for LabCorp (LH).
Here's Why You Should Retain Myriad Genetics (MYGN) for Now
by Zacks Equity Research
Investors are optimistic about Myriad Genetics (MYGN) owing to strong testing volume growth and notable product launches.
LabCorp (LH) Gets FDA's EUA for Combined Home Collection Kit
by Zacks Equity Research
The EUA for LabCorp's (LH) combined home collection kit can enable health-care providers to identify and treat individuals suspected of COVID-19 or influenza A/B infection.
LabCorp (LH) Bolsters RA Testing by Adding Myriad's Vectra
by Zacks Equity Research
According to LabCorp (LH), Vectra and the related IP and other assets from Myriad Genetics' autoimmune business complement its prior business activity.
Illumina (ILMN), Merck Ink Cancer Companion Diagnostics Deal
by Zacks Equity Research
Illumina (ILMN) collaborated with Merck to develop and commercialize companion diagnostics to identify ovarian cancer patients with positive HRD status for treatment with LYNPARZA.
Agilent (A) Boosts PD-L1 IHC 22C3 pharmDX Assay Use in Europe
by Zacks Equity Research
Agilent Technologies (A) boosts presence in the companion diagnostics market by expanding the use of PD-L1 IHC 22C3 pharmDx assay for esophageal cancer treatment in Europe.
Myriad Genetics (MYGN) Q2 Earnings Beat, Gross Margin Rises
by Zacks Equity Research
Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment has managed to drive Q2 sales despite a challenging business environment.
Myriad Genetics (MYGN) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Myriad (MYGN) delivered earnings and revenue surprises of 271.43% and 13.60%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Myriad Genetics (MYGN) Divests Myriad RBM to Focus on Core Units
by Zacks Equity Research
Myriad Genetics' (MYGN) new divesture will enable company to accelerate the execution of transformation plan and drive growth.
Why Is Myriad (MYGN) Down 11.5% Since Last Earnings Report?
by Zacks Equity Research
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Myriad Genetics (MYGN) Sells myPath to Focus on Core Units
by Zacks Equity Research
Myriad Genetics' (MYGN) new divesture will provide the company with growth capital for future investments.
Myriad Genetics' (MYGN) GeneSight Test Rollout Initiated by IPM
by Zacks Equity Research
Myriad Genetics' (MYGN) GeneSight testing distribution initiated through IPM will help clinicians and patients assess individual's response to certain medications.
Hologic (HOLX) ThinPrep Genesis Processor Gets FDA Approval
by Zacks Equity Research
Hologic's (HOLX) ThinPrep Genesis processor offers new automation capabilities and workflow enhancements.
Myriad Genetics (MYGN) Beats on Q1 Earnings and Revenues
by Zacks Equity Research
Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment has managed to drive Q1 sales despite pandemic-led business challenges.
Myriad Genetics (MYGN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Myriad (MYGN) delivered earnings and revenue surprises of 40.00% and 11.54%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
3 Women Healthcare Stocks With Solid Growth Potential Amid COVID-19
by Sriparna Ghosal
Let's take a look at the three women healthcare MedTech stocks performing well lately.
Myriad Genetics' (MYGN) myChoice Gets Additional Reimbursement
by Zacks Equity Research
Myriad Genetics' (MYGN) myChoice test's additional reimbursement will now make it available for use in first-line treatment of advanced ovarian cancer patients.
Why Is Myriad (MYGN) Down 6.5% Since Last Earnings Report?
by Zacks Equity Research
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Myriad Genetics (MYGN) Collaborates to Advance Oncology Care
by Zacks Equity Research
Myriad Genetics (MYGN) to provide a comprehensive offering utilizing germline genetic testing and somatic tumor profiling via latest collaboration with Intermountain Precision Genomics.
Myriad Genetics (MYGN) Beats on Q2 Revenues, Earnings in Line
by Zacks Equity Research
Myriad Genetics' (MYGN) sales in majority of the operating segments improved in the quarter despite pandemic-led business challenges.